Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 283-286

  Bain, C ^a   Merrouche, Y ^a   Puisieux, I ^a   Blay, J Y ^a   Negrier, S ^a   Bonadona, V ^a   Lasset, C ^a   Lanier, F ^a   Duc, A ^a   Gebuhrer, L ^b   Philip, T ^a   Favrot, M C ^a  

^a CENTRE LÉON BÉRARD   (France)

^b Centre de Transfusion Sanguine   (France)

Author keywords

HLA; Immunotherapy; Interleukin 2; Renal cell carcinoma

Indexed keywords

HLA A ANTIGEN; INTERLEUKIN 2; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; FEMALE; HLA SYSTEM; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL;

EID: 8044239627     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.46     Document Type: Article

References (21)

1. Atzpodien J, Korfer A, Franks CR, Poliwoda H and Kirchner H (1990) Home therapy with recombinant IL-2 and recombinant interferon alpha 2B in advanced human malignancies. Lancet 335: 1509-1512
2. Bain C, Merouche Y, Puisieux I, Duc A, Colombo MP and Favrol MC (1996) B7.1 gene transduclion of human renal cell carcinoma cell lines restores the proliferative response and cytotoxic function of allogenic T cells. Int J Cancer 67: 769-776
3. Bernhard H, Karbach J, Wölfel T, Busch P, Störkel S, Stöckle M, Wolfel C, Seliger B, Huber C, Meyer Sum Büschenfelde KH and Knuth A (1994) Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2 restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer 59: 837-842
4. Blay JY, Négrier S, Cornbaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko, JF, Philip T and Favrol M (1992) Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322
5. Dellon AL, Rogentine Jr GN and Chretien PB (1975) Prolonged survival in broncogenic carcinoma associated with HL-A antigens W-19 and HL-A5: a preliminary report. J Nucl Cancer Inst 54: 1283-1286
6. Falk J and Osoba D (1971) HL-A antigens and survival in Hodgkin's disease. Lancet 1118-1121
7. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53: 5613-5616
8. Kantor AF, McLaughlin JK, Blattner WA, Bach FH, Blot WJ, Schuman LM and Fraumeni JR JF (1983) HLA antigens in renal cell carcinoma. Cancer Res 43: 2330-2333
9. Lilly F, Boyse EA and Old LJ (1964) Genetic basis of susceptibility to viral leukaemogenesis. Lancet 1207-1209
10. Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE and Parkinson DR (1995) HLA associations in the antitumor response against malignant melanoma. J Immunother 18: 242-252
11. Merrouche Y, Négrier S, Bain C, Combaret V, Mercatello A, Coronel B, Moskovtchenko JF, Tolstoshev P, Moen R, Philip T and Favrot MC (1995) Clinical application of retroviral gene transfer in oncology: Results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 13: 410-418
12. Miller RG Jr (1981) Simultaneous Statistical Inference. Springer-Verlag New York
13. Mitchell MS, Harel W and Groshen S (1992) Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10: 1158-1164
14. Négrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacono A, Cleton FS, Israel L, Jasmin C, Rugarli C, Masse HVD, Thatcher N, Symann M, Bartsch HH, Bergmann L, Bijman JT, Palmer PA and Franks CR (1989) Interleukin-2 with or without LAK cells in metastatic renal carcinoma: a report of a European multicentric study. Eur J Cancer Clin Oncol 25: S21-S28
15. Oliver RTD, Pillai A, Klouda PT and Lawler SD (1977) HLA linked resistance factors and survival in acute myelogenous leukemia. Cancer 39: 2337-2341
16. Rosenberg SA, Lotze ML, Muul LM, Chang AE, Leitman S, Avis FP, Linehan WM, Robertson GM, Lee RE, Rubin JT, Seipp CA, Simpson C and White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889-897
17. Rubin JT, Duquesnoy R, Simonis B, Adams S, Lee J and Lotze MT (1995) HLA-DQI is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther Immunol 2: 1-6
18. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G and Segurado OG (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. J Immunol 151: 4209-4220
19. Sheibenbogen C, Keilholz U, Mytilineos J, Suciu S, Manasterski M and Hunstein W (1994) HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res 4: 191-194
20. Wang Q, Redman C, Tubbs R, Olencki T, Klein E, Kudoh S, Finke J and Bukowski RM (1995) Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 61: 780-785
21. West WH, Taner KW, Yanelli JR, Marshall GD, Orr DW, Thurmann GB and Oldham RT (1987) Constant infusion recombinant IL-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898-905